Wisevoter
World

Morgans Set New Price Target for Imricor

Analysts issued a report targeting a share price of $2.90 for the medical device firm.

Updated on Oct. 1, 2026 in Healthcare

Isometric editorial illustration of a stylized medical catheter tip, representing cardiac guidance technology in a clean, clinical aesthetic.
Morgans analysts set a new price target of $2.90 for Imricor Medical Systems, anticipating significant upside for the cardiac device company. AI Illustration. Upload story photo >

Live Poll

Is now a good time to invest in individual stocks rather than broader index funds?

On October 2, 2026, analysts at Morgans released a new research report establishing a share price target of $2.90 for Imricor Medical Systems. The company, which currently trades at $1.56, has seen its value decline by more than 20 percent since joining the S&P/ASX 300 Index.

Why it matters

The new target suggests a potential upside of 85.9 percent as the firm seeks to expand the commercial adoption of its magnetic resonance-guided cardiac technology. Investors are watching to see if upcoming milestones will help the company recover its market valuation of $568.3 million.

Imricor holds a market valuation of $568.3 million and has secured FDA approval for a manufacturing module covering seven products. The target price of $2.90 represents an 85.9 percent upside from the current trading price of $1.56.

The players

Imricor Medical Systems

This medical device company specializes in tools for real-time magnetic resonance-guided cardiac procedures.

Morgans

This is a financial services firm that provides investment research and market analysis.

Philips

This multinational technology company maintains a collaborative partnership with Imricor to integrate MRI platforms.

Children's Medical Center Dallas

This healthcare institution recently purchased Imricor's NorthStar mapping and guidance technology.

The details

Imricor utilizes specialized catheters designed for real-time magnetic resonance guidance, supported by a strategic integration with Philips cardiac systems. Children's Medical Center Dallas recently adopted the NorthStar mapping and guidance system as the company targets expansion into a market containing 250 children's hospitals and 2,000 adult facilities in the United States.

Timeline

  1. Morgans issued its research report on October 2, 2026.

  2. Company milestones are expected to be announced over the next three to six months.

Market Landscape

Imricor's performance is closely tied to its standing within the S&P/ASX 300 Index, where it has struggled since inclusion. The firm is now attempting to gain market share by positioning its technology against traditional cardiac mapping systems globally.

Investors currently face a volatile environment as the stock trades significantly below the analyst's target price. Future share stability remains dependent on the firm's ability to drive commercial adoption across the Philips global network.

The takeaway

Imricor is banking on the integration of its proprietary tools with established hospital MRI platforms to scale its operations. Potential investors should monitor upcoming milestones closely as the company attempts to close the gap between its current market price and analyst projections.

Further reading

For broader industry analysis, visit the Healthcare section.

Source note: This article includes information reported by Motley Fool Australia.

Live Poll

Is now a good time to invest in individual stocks rather than broader index funds?